# Hepatitis C Re-Treatment Recommendations

If you have been treated for hepatitis C before, here are the recommendations for re-treatment for all genotypes from the [American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA)](#).

AASLD HCV Re-treatment Recommendations for People Who Failed Prior Peginterferon and Ribavirin Treatment without Decompensated Cirrhosis or Certain Co-existing Medical Conditions, such as HCV Recurrence Post-Liver Transplant (Medications are listed first by evidence level according to the [HCVGuidelines.org](http://HCVGuidelines.org), then listed alphabetically.)

<table>
<thead>
<tr>
<th>Genotype 1a</th>
<th>Recommended</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>No cirrhosis</td>
<td>Epclusa* for 12 weeks</td>
<td>Daklinza + Sovaldi for 12 weeks</td>
</tr>
<tr>
<td></td>
<td>Harvoni* for 12 weeks</td>
<td>Zepatier + ribavirin for 16 weeks (with baseline</td>
</tr>
<tr>
<td></td>
<td>Mavyret for 8 weeks</td>
<td>NS5A RASs**)</td>
</tr>
<tr>
<td></td>
<td>Zepatier for 12 weeks (without baseline NS5A RASs**)</td>
<td></td>
</tr>
<tr>
<td>Compensated cirrhosis</td>
<td>Epclusa* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Harvoni* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavyret for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zepatier for 12 weeks (without baseline NS5A RASs**)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavyret for 12 weeks</td>
<td></td>
</tr>
<tr>
<td>Genotype 1b</td>
<td>Epclusa* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td>No cirrhosis</td>
<td>Harvoni* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavyret for 8 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zepatier for 12 weeks</td>
<td></td>
</tr>
<tr>
<td>Compensated cirrhosis</td>
<td>Epclusa* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Harvoni* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavyret for 8 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zepatier for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavyret for 12 weeks</td>
<td></td>
</tr>
<tr>
<td>Genotype 2</td>
<td>Epclusa* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td>No cirrhosis</td>
<td>Harvoni* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavyret for 8 weeks</td>
<td></td>
</tr>
<tr>
<td>Geontype 2</td>
<td>Epclusa* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td>Compensated cirrhosis</td>
<td>Harvoni* for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavyret for 12 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavyret for 16 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mavyret for 12 weeks</td>
<td>Vosevi for 12 weeks (with Y93H RASs**)</td>
</tr>
</tbody>
</table>

---

**Legend:**
- **Epclusa**: A combination of glecaprevir/pibrentsvir
- **Harvoni**: A combination of ledipasvir/sofosbuvir
- **Mavyret**: A combination of ombitasvir/paritaprevir/ritonavir/daclatasvir
- **Zepatier**: A combination of asunaprevir/sofosbuvir
- **Daklinza**: Daclatasvir oral solution
- **Sovaldi**: Sofosbuvir oral solution
- **Vosevi**: Velpatasvir, voxilaprevir, and voxilaprevir
- **RASs**: Resistance-associated substitutions
<table>
<thead>
<tr>
<th>Genotype</th>
<th>Status</th>
<th>Treatment Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>No Cirrhosis</td>
<td>Recommended: Epclusa* for 12 weeks, Mavyret for 8 weeks, Harvoni* for 12 weeks, Zepatier for 12 weeks for responder-relapsers to prior treatment.</td>
</tr>
<tr>
<td>4</td>
<td>Compensated Cirrhosis</td>
<td>Recommended: Epclusa* for 12 weeks, Mavyret for 12 weeks, Zepatier for 12 weeks for responder-relapsers to prior treatment.</td>
</tr>
<tr>
<td>5</td>
<td>No Cirrhosis</td>
<td>Recommended: Epclusa* for 12 weeks, Harvoni* for 12 weeks, Mavyret for 8 weeks.</td>
</tr>
<tr>
<td>5</td>
<td>Compensated Cirrhosis</td>
<td>Recommended: Mavyret for 12 weeks, Epclusa* for 12 weeks, Harvoni* for 12 weeks.</td>
</tr>
<tr>
<td>6</td>
<td>No Cirrhosis</td>
<td>Recommended: Epclusa* for 12 weeks, Harvoni* for 12 weeks, Mavyret for 8 weeks.</td>
</tr>
<tr>
<td>6</td>
<td>Compensated Cirrhosis</td>
<td>Recommended: Mavyret for 12 weeks, Epclusa* for 12 weeks, Harvoni* for 12 weeks.</td>
</tr>
</tbody>
</table>

**Genotype 1a**

- **No Cirrhosis**
  - **Recommended**: Epclusa* for 12 weeks, Harvoni* for 12 weeks, Mavyret for 8 weeks, Zepatier for 12 weeks (without baseline NS5A RASs**).  
  - **Alternative**: Daklinza + Sovaldi for 12 weeks, Zepatier + ribavirin for 16 weeks (with baseline NS5A RASs**).  

- **Compensated Cirrhosis**
  - **Recommended**: Epclusa* for 12 weeks, Zepatier for 12 weeks (without baseline NS5A RASs**), Mavyret for 12 weeks.  
  - **Alternative**: Harvoni* + ribavirin for 12 weeks, Zepatier + ribavirin for 16 weeks (with baseline NS5A RASs**).
Genotype 1b
no cirrhosis

Recommended
• Epclusa* for 12 weeks
• Harvoni* for 12 weeks
• Mavyret for 8 weeks
• Zepatier for 12 weeks

Alternative
• Daklinza + Sovaldi for 12 weeks

Genotype 1b
compensated cirrhosis

Recommended
• Epclusa* for 12 weeks
• Zepatier for 12 weeks
• Mavyret for 12 weeks

Alternative
• Harvoni* + ribavirin for 12 weeks

Genotype 2
no cirrhosis

Recommended
• Epclusa* for 12 weeks
• Mavyret for 8 weeks

Alternative
• Daklinza + Sovaldi for 12 weeks

Genotype 2
compensated cirrhosis

Recommended
• Epclusa* for 12 weeks
• Mavyret for 12 weeks

Alternative
• Daklinza + Sovaldi for 16 to 24 weeks

Genotype 3
no cirrhosis

Recommended
• Epclusa* for 12 weeks
• Daklinza + Sovaldi for 12 weeks
• Mavyret for 16 weeks
• Vosevi for 12 weeks (with Y93H RASs**)

Genotype 3
compensated cirrhosis

Recommended
• Zepatier + Sovaldi for 12 weeks
• Vosevi for 12 weeks

Alternative
• Epclusa* + ribavirin for 12 weeks
• Mavyret for 16 weeks

Genotype 4
no cirrhosis

Recommended
• Epclusa* for 12 weeks
• Mavyret for 8 weeks
• Harvoni* for 12 weeks
• Zepatier for 12 weeks for responder-relapsers to prior treatment

Alternative
• Zepatier + ribavirin for 16 weeks if prior treatment failed to suppress HCV
Geontype 4
compensated cirrhosis

Recommended
• Epclusa* for 12 weeks
• Mavyret for 12 weeks
• Zepatier for 12 weeks for responder-relapsers to prior treatment

Alternative
• Harvoni* + ribavirin for 12 weeks
• Zepatier + ribavirin for 16 weeks if prior treatment failed to suppress HCV

Genotype 5
no cirrhosis

Recommended
• Epclusa* for 12 weeks
• Harvoni* for 12 weeks
• Mavyret for 8 weeks

Alternative

Genotype 5
compensated cirrhosis

Recommended
• Mavyret for 12 weeks
• Epclusa* for 12 weeks
• Harvoni* for 12 weeks

Alternative

Genotype 6
no cirrhosis

Recommended
• Epclusa* for 12 weeks
• Harvoni* for 12 weeks
• Mavyret for 8 weeks

Alternative

Genotype 6
compensated cirrhosis

Recommended
• Mavyret for 12 weeks
• Epclusa* for 12 weeks
• Harvoni* for 12 weeks

Alternative

*Generic version is available in the United States.

**RASs = resistance-associated substitutions (formerly RAVs or resistance-associated variants)

AASLD HCV Re-treatment Recommendations for People Who Failed Prior Treatment with Peginterferon, Ribavirin, and an HCV NS3 Protease Inhibitor (Incivek, Olysio, Victrelis)

(Medications are listed first by evidence level according to the HCVGuidelines.org, then listed alphabetically.)
**Genotype 1**

**no cirrhosis**

**Recommended**
- Epclusa* for 12 weeks
- Harvoni* for 12 weeks
- Mavyret for 12 weeks

**Alternative**
- Zepatier + ribavirin for 12 weeks for genotype 1b and genotype 1a without baseline NS5A RASs**; 16 weeks for genotype 1a with baseline NS5A RASs**

**Genotype 1**

**compensated cirrhosis**

**Recommended**
- Epclusa* for 12 weeks
- Mavyret for 12 weeks

**Alternative**
- Zepatier + ribavirin for 12 weeks for genotype 1b and genotype 1a without baseline NS5A RASs**; 16 weeks for genotype 1a with baseline NS5A RASs**

---

*Generic version is available in the United States.

** RASs = resistance-associated substitutions (formerly RAVs or resistance-associated variants)

**

AASLDHCV Re-treatment Recommendations for People Who Failed Prior Non-NS5A Inhibitor Treatment Containing Sovaldi (Medications are listed first by evidence level according to the [HCVGuidelines.org](http://HCVGuidelines.org), then listed alphabetically.)

**Genotype 1**

**no cirrhosis**

**Recommended**
- Vosevi for 12 weeks
- Epclusa* for 12 weeks
- Mavyret for 12 weeks

**Alternative**
- Harvoni* + ribavirin for 12 weeks (except when previously failed Olysio treatment)

**Genotype 1**

**compensated cirrhosis**

**Recommended**
- Vosevi for 12 weeks
- Epclusa* for 12 weeks
- Mavyret for 12 weeks

**Genotype 2**

**no cirrhosis**

**Recommended**
- Epclusa* for 12 weeks
- Mavyret for 12 weeks

**Genotype 2**

**compensated cirrhosis**

**Recommended**
- Epclusa* for 12 weeks
- Mavyret for 12 weeks
| Genotype 3 | no cirrhosis | • Vosevi for 12 weeks |
| Genotype 3 | compensated cirrhosis | • Vosevi + ribavirin for 12 weeks |
| Genotype 4 | no cirrhosis | • Vosevi for 12 weeks |
| Genotype 4 | compensated cirrhosis | • Vosevi for 12 weeks |
| Genotype 5 or 6 | no cirrhosis | • Vosevi for 8 weeks |
| Genotype 5 or 6 | compensated cirrhosis | • Vosevi for 12 weeks |

| Genotype 1 | no cirrhosis | • Vosevi for 12 weeks |
| Genotype 1 | compensated cirrhosis | • Vosevi for 12 weeks |

| Genotype 1 | no cirrhosis | Recommended | • Vosevi for 12 weeks |
| Genotype 1 | compensated cirrhosis | • Epclusa* for 12 weeks |
| Genotype 2 | no cirrhosis | • Mavyret for 12 weeks |
| Genotype 2 | compensated cirrhosis | • Epclusa* for 12 weeks |

| Genotype 3 | no cirrhosis | Recommended | • Vosevi for 12 weeks |
| Genotype 3 | no cirrhosis | Alternative | • Vosevi for 12 weeks |

Alternative

Harvoni* + ribavirin for 12 weeks (except when previously failed Olysio treatment)

Mavyret for 12 weeks
<table>
<thead>
<tr>
<th>Genotype 3 compensate cirrhosis</th>
<th>Recommended</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 4 no cirrhosis</td>
<td></td>
<td>Vosevi for 12 weeks</td>
</tr>
<tr>
<td>Genotype 4 compensated cirrhosis</td>
<td>Vosevi for 12 weeks</td>
<td></td>
</tr>
<tr>
<td>Genotype 5 or 6 no cirrhosis</td>
<td></td>
<td>Vosevi for 8 weeks</td>
</tr>
<tr>
<td>Genotype 5 or 6 compensated cirrhosis</td>
<td>Vosevi for 12 weeks</td>
<td></td>
</tr>
</tbody>
</table>

*Generic version is available in the United States.

AASLD HCV Re-treatment Recommendations for People Who Failed Prior Treatment with an NS5A Inhibitor Direct-Acting Antiviral (DAA) (Medications are listed first by evidence level according to the HCVGuidelines.org, then listed alphabetically.)

<table>
<thead>
<tr>
<th>Genotype 1 no cirrhosis or compensated cirrhosis</th>
<th>Recommended</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 3 no cirrhosis or compensated cirrhosis</td>
<td>Vosevi for 12 weeks (+ ribavirin if cirrhosis and prior NS5A failure)</td>
<td></td>
</tr>
<tr>
<td>Genotype 4, 5, 6 no cirrhosis or compensated cirrhosis</td>
<td>Vosevi for 12 weeks</td>
<td></td>
</tr>
</tbody>
</table>

* Mavyret for 16 weeks (except if previously treated with NS3/4 protease inhibitor DAA)
**Genotype 1**

**no cirrhosis or compensated cirrhosis**

Recommended • Vosevi for 12 weeks

Alternative • Mavyret for 16 weeks (except if previously treated with NS3/4 protease inhibitor DAA)

**Genotype 3**

**no cirrhosis or compensated cirrhosis**

Recommended • Vosevi for 12 weeks (+ ribavirin if cirrhosis and prior NS%A failure)

Alternative

**Genotype 4, 5, 6**

**no cirrhosis or compensated cirrhosis**

Recommended • Vosevi for 12 weeks

Alternative

For those needing information about medication for advanced liver disease, visit [HCV treatment recommendations for those with decompensated cirrhosis](https://www.hepmag.com/basics/hepatitis-c-basics/hepatitis-c-retreatment-recommendations). Click on [HCV Treatment Post-Transplantation](https://www.hepmag.com/basics/hepatitis-c-basics/hepatitis-c-retreatment-recommendations) for information about HCV recurrence following liver transplantation.

Last Reviewed: March 11, 2019